156 related articles for article (PubMed ID: 35276437)
41. Relapse of Lymphangioleiomyomatosis Five Years after Bilateral-Lung Transplantation.
Heshmatnia J; Mirenayat MS; Rezaei M; Bongomin F; Bakhshayeshkaram M; Tabarsi P; Sheikhy K; Mortezaee V
Arch Iran Med; 2021 Sep; 24(9):701-703. PubMed ID: 34816687
[TBL] [Abstract][Full Text] [Related]
42. Lymphangioleiomyomatosis: Current understanding and potential treatments.
Moir LM
Pharmacol Ther; 2016 Feb; 158():114-24. PubMed ID: 26713679
[TBL] [Abstract][Full Text] [Related]
43. Risk factors for stomatitis in patients with lymphangioleiomyomatosis during treatment with sirolimus: A multicenter investigator-initiated prospective study.
Kitamura N; Seyama K; Inoue Y; Nagai K; Suzuki M; Moriyama H; Takada T; Tazawa R; Hirai T; Mishima M; Hayashida M; Hirose M; Arai T; Sugimoto C; Hattori N; Watanabe K; Tamada T; Akazawa K; Tanaka T; Nakata K
Pharmacoepidemiol Drug Saf; 2017 Oct; 26(10):1182-1189. PubMed ID: 28752672
[TBL] [Abstract][Full Text] [Related]
44. Alterations in Polyamine Metabolism in Patients With Lymphangioleiomyomatosis and Tuberous Sclerosis Complex 2-Deficient Cells.
Tang Y; El-Chemaly S; Taveira-Dasilva A; Goldberg HJ; Bagwe S; Rosas IO; Moss J; Priolo C; Henske EP
Chest; 2019 Dec; 156(6):1137-1148. PubMed ID: 31299246
[TBL] [Abstract][Full Text] [Related]
45. The efficacy and safety of pharmacological treatments for lymphangioleiomyomatosis.
Wang Q; Luo M; Xiang B; Chen S; Ji Y
Respir Res; 2020 Feb; 21(1):55. PubMed ID: 32059669
[TBL] [Abstract][Full Text] [Related]
46. Predicting Individualized Lung Disease Progression in Treatment-Naive Patients With Lymphangioleiomyomatosis.
Palipana AK; Gecili E; Song S; Johnson SR; Szczesniak RD; Gupta N
Chest; 2023 Jun; 163(6):1458-1470. PubMed ID: 36610667
[TBL] [Abstract][Full Text] [Related]
47. Reduction in size of renal angiomyolipoma after treatment with everolimus in lung transplantation due to lymphangioleiomyomatosis.
Bujalance-Cabrera C; Vaquero-Barrios JM; Redel-Montero J; Caballero-Ballesteros L; Requejo-Jiménez A; Santos-Luna F
Arch Bronconeumol; 2012 Dec; 48(12):479-81. PubMed ID: 22444789
[TBL] [Abstract][Full Text] [Related]
48. Lymphangioleiomyomatosis.
Xu KF; Xu W; Liu S; Yu J; Tian X; Yang Y; Wang ST; Zhang W; Feng R; Zhang T
Semin Respir Crit Care Med; 2020 Apr; 41(2):256-268. PubMed ID: 32279296
[TBL] [Abstract][Full Text] [Related]
49. Lung transplantation for lymphangioleiomyomatosis: the European experience.
Benden C; Rea F; Behr J; Corris PA; Reynaud-Gaubert M; Stern M; Speich R; Boehler A
J Heart Lung Transplant; 2009 Jan; 28(1):1-7. PubMed ID: 19134523
[TBL] [Abstract][Full Text] [Related]
50. Sirolimus for lymphangioleiomyomatosis lesions.
Egan JJ; Remund KF; Corris P
N Engl J Med; 2008 May; 358(18):1963-4; author reply 1964. PubMed ID: 18450609
[No Abstract] [Full Text] [Related]
51. Inhibition of Growth of TSC2-Null Cells by a PI3K/mTOR Inhibitor but Not by a Selective MNK1/2 Inhibitor.
Evans JF; Rue RW; Mukhitov AR; Obraztsova K; Smith CJ; Krymskaya VP
Biomolecules; 2019 Dec; 10(1):. PubMed ID: 31878201
[TBL] [Abstract][Full Text] [Related]
52. Durability of Sirolimus for Lymphangioleiomyomatosis.
Martirossian A; Shah S; Carrete L; Valle J; Valentine V
Am J Med Sci; 2017 Dec; 354(6):603-607. PubMed ID: 29208258
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis.
Ando K; Kurihara M; Kataoka H; Ueyama M; Togo S; Sato T; Doi T; Iwakami S; Takahashi K; Seyama K; Mikami M
Respir Investig; 2013 Sep; 51(3):175-83. PubMed ID: 23978644
[TBL] [Abstract][Full Text] [Related]
54. Sirolimus treatment for recurrent lymphangioleiomyomatosis after lung transplantation.
Chen F; Omasa M; Kondo N; Fujinaga T; Shoji T; Sakai H; Bando T
Ann Thorac Surg; 2009 Jan; 87(1):e6-7. PubMed ID: 19101258
[TBL] [Abstract][Full Text] [Related]
55. Metabolic Impact of Rapamycin (Sirolimus) and B-Estradiol Using Mouse Embryonic Fibroblasts as a Model for Lymphangioleiomyomatosis.
Marsh KM; Schipper D; Ferng AS; Johnson K; Fisher J; Knapp S; Dicken D; Khalpey Z
Lung; 2017 Aug; 195(4):425-430. PubMed ID: 28577037
[TBL] [Abstract][Full Text] [Related]
56. Mammalian target of rapamycin signaling and autophagy: roles in lymphangioleiomyomatosis therapy.
Yu J; Parkhitko AA; Henske EP
Proc Am Thorac Soc; 2010 Feb; 7(1):48-53. PubMed ID: 20160148
[TBL] [Abstract][Full Text] [Related]
57. Immunohistological features related to functional impairment in lymphangioleiomyomatosis.
Nascimento ECTD; Baldi BG; Mariani AW; Annoni R; Kairalla RA; Pimenta SP; da Silva LFF; Carvalho CRR; Dolhnikoff M
Respir Res; 2018 May; 19(1):83. PubMed ID: 29739412
[TBL] [Abstract][Full Text] [Related]
58. Rates of change in FEV
Taveira-DaSilva AM; Julien-Williams P; Jones AM; Stylianou M; Moss J
Eur Respir J; 2018 Apr; 51(4):. PubMed ID: 29519926
[TBL] [Abstract][Full Text] [Related]
59. Bronchial involvement in advanced stage lymphangioleiomyomatosis: histopathologic and molecular analyses.
Hayashi T; Kumasaka T; Mitani K; Okada Y; Kondo T; Date H; Chen F; Oto T; Miyoshi S; Shiraishi T; Iwasaki A; Hara K; Saito T; Ando K; Kobayashi E; Gunji-Niitsu Y; Kunogi M; Takahashi K; Yao T; Seyama K
Hum Pathol; 2016 Apr; 50():34-42. PubMed ID: 26997436
[TBL] [Abstract][Full Text] [Related]
60. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.
Bissler JJ; McCormack FX; Young LR; Elwing JM; Chuck G; Leonard JM; Schmithorst VJ; Laor T; Brody AS; Bean J; Salisbury S; Franz DN
N Engl J Med; 2008 Jan; 358(2):140-51. PubMed ID: 18184959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
